The national team's rapid layout MNC heavy gold bet: standing in the air mouth of the medical big data will go where

The field of big data in healthcare is starting to get restless.
September 7th, Zero-Yuan Technology announced that it had obtained 700 million yuan in D-plus round financing, and began to accelerate the overall acceleration of the "medical-drug-risk" commercial closure.
is believed to be the first unicorn company in the field of medical big data and artificial intelligence, having previously received multiple rounds of financing.
September 3rd, Jia and Meikang Sprint, one of the earliest enterprises in China to engage in medical information software research and development and industrialization, proposed to raise no more than 750 million yuan.
, on August 24th Medical Technology Co., a medical technology company that provides solutions based on big data and artificial intelligence technology, submitted its main board listing application to the Hong Kong Stock Exchange.
but these companies have one thing in common: the involvement of the national team's capital forces behind them.
Technology, one of the world's largest sovereign wealth funds, includes China Investment Corporation, one of its 1 billion yuan D-round investors in July 2018.
jia and Meikang prospects disclosed that Guoshou Chengda's shareholding ratio reached 18.92%, (Guoshou Chengda is Chinese Shou Group's professional alternative investment management platform).
the shareholders of the soon-to-be-listed Medical Duyun are Guiyang Big Data Industry Group (0.55%) of Guiyang Government and Guiyang Industrial and Commercial Industry Investment Group (0.66%).
, several national team-backed medical big data companies have been set up this year.
8th, the operation headquarters of United Health Care Big Data Technology Co., Ltd., which was deployed by China's National Health And Health Commission and led by China Mobile, was officially unveiled.
This is China's first "state-owned enterprises leading investment, local governments, financial institutions and medical information enterprises to participate in the state-owned capital as the main body and have a market-oriented mechanism" of the health care big data industry group.
for the state to set up a health care big data industry group, China-Thai Securities proposed that the medical big data industry will be in the wind.
In addition, China-funded Data Technology Co., Ltd. and the National Medical Emergency Protection System Internet Platform Company, these two pharmaceutical big data companies with the National Pharmaceutical Group, China Resources Pharmaceuticals and other circulation giants, from the field of pharmaceutical circulation, to create production, circulation, reserves and other links of medical and pharmaceutical emergency protection platform, to achieve the information and data interoperability of medical and pharmaceutical materials, convergence and construction of medical and pharmaceutical ecological chain.
, China Data Technology Co., Ltd. is one of the three major shareholders of China Medical And Pharmaceutical Emergency Protection Platform Co., Ltd., accounting for 39% of the shares.
China Capital Data was established on July 8 this year, the majority shareholder is THE DATA, holding 27.5 percent of the shares, the legal representative, chairman is Li Shifeng.
and THE DATA is a health care big data industry development platform led by China Electronics under the guidance of the National Health and Safety Commission.
, the controlling shareholder of China National Pharmaceutical Emergency Protection Platform Co., Ltd., is also unusual.
Chinese medicine intelligence is also a new joint venture.
the evening of July 6, China National Pharmaceutical Holdings announced that it would enter into a joint venture agreement with China Bio, Guangdong Global, Hyundai Pharmaceuticals and General Hospital for the establishment of a joint venture.
joint venture proposed the name of China Pharmaceutical Intelligent Technology (Shanghai) Co., Ltd., after the establishment of the joint venture, will invest in the construction of a national medical and pharmaceutical emergency protection system Internet platform company.
Pharmaceutical Holdings invested 60 million yuan in cash, accounting for 60% of the joint venture, while other units showed 10 million yuan, accounting for 10% of the total joint venture.
the company, ong Jieming, deputy director of SASAC, has said it is working to build the platform into the first Internet company based on the digital economy.
only two months from the July 6 announcement to August 29th, china's drug intelligence has begun to sell, can be described as "god speed".
these two "newborn calves" are also a difficult task in the future.
What they have to do is open up the medical supply chain data, break down the data silos, make the data the same standard, and realize the interoperability and sharing between provinces and even countries, they have to do is a systematic big project.
these two companies, whether in the equity structure, or team settings, data collection system, are different from the simple state-owned enterprises, state-owned enterprises or simple private enterprises.
why set up two "new" companies to do this? "They are using an innovative corporate system and an innovative data system to build a big data system for Chinese medicine, " an industry insider told E Pharmaceuticals.
most valuable asset in the future is data, which must be large enough to be valuable.
Specific to the field of medical, pharmaceutical, in terms of data collection, whether national or local, or even small and medium-sized enterprises have some small exploration, but large-scale, national, from logistics to the field of production, hospital data collection and application is far from enough.
to realize the interconnection of data, it is difficult to achieve by state-owned enterprises and local state-owned enterprises alone, which requires the establishment of a new model.
"through this new model, new companies, new teams, pooling the resources of all parties to do, relatively more likely to achieve the goal."
In this outbreak, the disadvantages of decentralized information construction have obviously been revealed, the current medical industry information and data concentration is still in a relatively early and low-level stage, especially to achieve the goal of emergency protection, to achieve the provincial and provincial, between the country's information connectivity and research and development innovation between the need for efforts.
Multinational pharmaceutical companies aim for ecological construction and this EY has made a special report on the compound annual growth rate of 40.5%, is expected to grow to 57.7 billion yuan by 2024 in China's medical big data solutions market, multinational pharmaceutical companies will not miss.
But for MNC, the mastery and mining of big health data is no longer limited to providing scientific evidence and improving the level of diagnosis and treatment, we have found from a number of multinational pharmaceutical companies and domestic enterprises in the big data cooperation, "one-stop, closed-loop solutions," "integrated medical health services," "multi-faceted patient management" has become a high-frequency vocabulary.
as early as 2014, Pfizer Investment Co., Ltd. and Capital Medical University affiliated Beijing Anzhen Hospital set up the "Anzhen-Pfizer Cardiovascular Data Center."
media reported at the time that it was "the opening of a blueprint for big health care in China".
center aims to provide evidence-based evidence for effective cardiovascular disease prevention and treatment with advanced big data analytics.
2017, AstraZenecom signed a partnership agreement with Peking University Data Research Institute to build a health care big data lab.
of this school-enterprise collaboration is to provide scientific evidence to patients, doctors, and governments through big data and big data analytics.
, which is unlike AstraZeneta, Novarma opted for a cross-border partnership with internet giant Tencent in 2018.
will work together to create a practical model of patient service innovation, and gradually promote a comprehensive, full life cycle of integrated health management.
At the same time, the two sides will explore and promote the process of medical informatization, digitization and intelligence, improve patient care processes and experiences, and explore the application of big data and artificial intelligence technologies in clinical diagnosis and treatment, disease surveillance and scientific research, and jointly promote the balanced and full development of medical and health undertakings.
Same year, GSK chose to team up with JD.com to deeply lay out Internet healthcare, and both are based on big data analytics on user behavior to provide more accurate, customized disease education and other services, providing patients with one-stop, closed-loop solutions.
October 2019, Bayer reached an agreement with Healthy, which focuses on online chronic disease management services.
In addition, the two sides will cooperate in drug traceability, intelligent medical care, chronic disease management, patient education, doctor education, grass-roots projects, medical big data, etc., to explore integrated medical and health services such as drug safety and doctor-patient education.
May this year, Lilly China cooperated with 1 Pharmaceutical Network.
Lilly China will rely on 1 drug network Internet technology service capabilities, combined with their own advantages in the field of diabetes, and jointly help diabetics to build a multi-faceted diabetes management platform, including disease management, disease education and patient support projects, to better help diabetics understand the disease knowledge, and home management, to provide patients with "doctor consultation and drug treatment" one-stop service solutions.
clearly, multinational pharmaceutical companies have also seen big healthcare data as an indispensable battleground.